NXEN Stock Overview
Focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nexien BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.014 |
| 52 Week High | US$0.05 |
| 52 Week Low | US$0.011 |
| Beta | 0.75 |
| 11 Month Change | -70.00% |
| 3 Month Change | -18.97% |
| 1 Year Change | -64.30% |
| 33 Year Change | -80.68% |
| 5 Year Change | -80.97% |
| Change since IPO | -99.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXEN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -29.5% | 2.6% | 0.5% |
| 1Y | -64.3% | 13.1% | 30.7% |
Return vs Industry: NXEN underperformed the US Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: NXEN underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| NXEN volatility | |
|---|---|
| NXEN Average Weekly Movement | 91.4% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NXEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NXEN's weekly volatility has increased from 63% to 91% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Richard Greenberg | www.nexienbiopharma.com |
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
Nexien BioPharma, Inc. Fundamentals Summary
| NXEN fundamental statistics | |
|---|---|
| Market cap | US$920.04k |
| Earnings (TTM) | -US$196.20k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.1x
P/E RatioIs NXEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXEN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$196.20k |
| Earnings | -US$196.20k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0028 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -83.8% |
How did NXEN perform over the long term?
See historical performance and comparison